Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1

Why It Matters

Oral GLP‑1 delivery could dramatically expand patient adoption, challenging the dominance of injectable diabetes treatments and reshaping market dynamics.

Key Takeaways

• Phase 2 trial shows 30% HbA1c reduction
• Oral bioavailability achieved 30% with fasting dosing
• Safety profile comparable to injectable GLP‑1s
• Potential to capture market share from Lilly, Novo
• FDA filing planned for 2027 based on data

Pulse Analysis

The GLP‑1 market, now worth over $30 billion, has been dominated by injectable products from Eli Lilly and Novo Nordisk. While these agents have transformed type‑2 diabetes care, their injection requirement remains a barrier for many patients. Structure Therapeutics has pursued an oral formulation using proprietary absorption enhancers, aiming to overcome gastrointestinal degradation and achieve clinically meaningful exposure. This approach reflects a broader industry trend toward patient‑friendly delivery systems, as insurers and providers increasingly favor therapies that improve adherence.

In the recent Phase 2 study, Structure’s oral GLP‑1 candidate enrolled 150 treatment‑naïve adults with uncontrolled diabetes. Over 24 weeks, participants experienced an average 30% drop in HbA1c, with 70% reaching the <7% target—a performance on par with leading injectables. The drug achieved roughly 30% oral bioavailability, a notable improvement over earlier attempts that struggled to exceed 10%. Safety monitoring revealed typical GLP‑1 class effects, such as mild gastrointestinal events, but no unexpected adverse events, bolstering confidence in its risk‑benefit profile.

If the forthcoming Phase 3 program confirms these findings, Structure could disrupt a market where incumbents command over 80% share. An oral GLP‑1 would appeal to patients hesitant about needles, potentially expanding the addressable population and driving higher prescription volumes. Investors are watching closely, as a successful launch could translate into significant revenue streams and strategic partnerships. Moreover, regulatory approval would signal a milestone for oral peptide therapeutics, encouraging further innovation across metabolic and cardiovascular indications.